Skip to main content
Search
Home    /    Insights & Resources

Insights & Resources

Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.

Texas life sciences in 2025 saw concentrated capital, declining innovation output and earlier‑stage clinical shifts shaping the ecosystem.
Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.
Explore Q3 2025 trends in Texas life sciences, from Series B collapse and pipeline bottlenecks to sector divergence and record late-stage capital.
Explore Weaver’s 2025 Corporate Responsibility Report, featuring our first double materiality assessment and updates on our sustainability progress.
Life sciences companies often overlook SOX in IPO prep. Discover how early action and targeted strategies can strengthen investor confidence.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.
Take a dive into the topic of impact investing, effects of market volatility, “greenwashing”, proposed SEC rules for ESG disclosures & evolving market reactions.
Updates to Form PF were designed to assess systemic risk and bolster regulatory oversight in the growing hedge fund industry. Find out more.
The SEC proposed new regulations to establish disclosure requirements for funds and advisers that market themselves as having an ESG focus.
Under the Investment Advisers Act of 1940, the SEC proposed a rule that would bring new audit and reporting requirements as well as prohibit certain actions.